CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has reported encouraging results from its Phase 3 clinical trial of BP11 biosimilar, a biosimilar to the widely used biologic drug Xolair (omalizumab). The announcement marks a key milesto...
In an interview with Thiruamuthan, Assistant Editor at India Pharma Outlook, Dr Kuber Jagdale, discusses how Indian API and pharma is shifting to data-driven, proactive EHS strategies using AI, IoT, and automation to improve compliance, safety, and o
Novartis is stepping up efforts to tackle gaps in care with its Novartis community health programs, expanding initiatives aimed at heart disease and cancer in underserved populations. The Novartis community health programs will grow from 11 to...
India is moving ahead with a digital portal to track narcotic drugs, a step aimed at tightening oversight on controlled medicines.The proposed digital portal to track narcotic drugs will create a centralized system to monitor the movement and use...
In an increasingly digital-first healthcare environment, more patients are turning to online searches, home remedies, and AI-driven tools to self-diagnose and make treatment decisions. A trend Paras Health flagged on World Health Day as a key...
A pioneering public health approach developed in West Bengal to combat Type 1 diabetes (T1D) is set to gain international traction, with several Southeast Asian countries expressing interest in adopting the model, marking a significa...
Aurobindo Pharma has secured a key Aurobindo Pharma USFDA approval to manufacture and market Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
The Telangana food adulteration crackdown was announced today by Health Minister Damodar Rajanarasimha, who said the government will roll out a dedicated system to curb unsafe and fake food.
Cancer drug price hike is back in focus as Indian pharmaceutical companies have sought a sharp increase in prices of key chemotherapy medicines, citing a surge in platinum costs that is hurting production viability.
US tariffs on patented pharma imports bring mixed impact for India, protecting generics but raising long-term risks for supply chains and investments.
.jpg)
, CDSCO.jpg)